• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Fulcrum Therapeutics, Inc. - Common Stock (NQ: FULC )

    4.350 +0.320 (+7.94%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,277,668
    Open 3.990
    Bid (Size) 4.200 (5)
    Ask (Size) 4.350 (1)
    Prev. Close 4.030
    Today's Range 3.955 - 4.390
    52wk Range 2.860 - 13.70
    Shares Outstanding 61,758,994
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Fulcrum Therapeutics to Participate in Upcoming December Conferences
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Expert Ratings For Fulcrum Therapeutics
    Via Benzinga

    Performance

    YTD
    -39.67%
    -39.67%
    1 Month
    +33.85%
    +33.85%
    3 Month
    +35.94%
    +35.94%
    6 Month
    -31.39%
    -31.39%
    1 Year
    -34.19%
    -34.19%

    More News

    Read More
    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 13, 2024
    Via Benzinga
    Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Preview: Fulcrum Therapeutics
    Via Benzinga
    Fulcrum Therapeutics's Earnings Outlook
    Via Benzinga
    Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views
    Via Benzinga
    Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
    Via Investor's Business Daily
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
    Via Investor's Business Daily
    FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14
    Via Talk Markets
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Dow Surges Over 100 Points; ModivCare Shares Plummet
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    Crude Oil Surges 3%; Kroger Posts Upbeat Earnings
    Via Benzinga
    Exposures Fossil Fuels
    Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial
    Via Benzinga
    US Stocks Mixed; Producer Prices Increase In August
    Via Benzinga
    Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
    Via Benzinga
    Fulcrum Therapeutics to Participate in Upcoming September Conferences
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.